



Biotech Daily

Monday June 15, 2009

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH UP; SUNSHINE UP 17%, PHYLOGICA DOWN 8%**
- * **PATRY'S ANIMAL TRIAL PAVES WAY TO HUMAN ANTI-CANCER STUDY**
- * **US PATENT FOR FLUOROTECHNICS; OFFICE MOVE**
- * **COMPUMEDICS GERMANY SIGNS \$300k CONTRACTS**
- * **CEPHALON PAYS EXTRA 5¢, EXTENDS ARANA TAKEOVER**
- * **SIENNA APPOINTS DR IAN MACREADIE CSO**

MARKET REPORT

The Australian stock market fell 0.75 percent on Monday June 15, 2009 with the S&P ASX 200 index down 30.5 points to 4,031.7 points.

Seventeen of the Biotech Daily Top 40 stocks were up, 13 fell, eight traded unchanged and two were untraded.

Sunshine Heart was best for the second trading day in a row, up one cent or 16.7 percent to seven cents with 116,500 shares traded, followed by Novogen up 9.0 percent to 85 cents and Labtech up 8.0 percent to 13.5 cents.

Acrux climbed 6.15 percent; Living Cell, Prana and Viralytics were up more than five percent; Polartech was up 3.1 percent; Bionomics, Genera, Nanosonics, Optiscan and Sirtex rose two percent or more; with Alchemia, Cellestis, Cochlear and Resmed up more than one percent.

Phylogica led the falls, down half a cent or 7.7 percent to six cents with 25,000 shares traded followed by Cytobia down 7.1 percent to 7.9 cents.

Avexa fell 4.35 percent with 1.6 million shares traded; Benitec and Tyrian both fell 3.6 percent; Bone, Clinuvel and Progen shed more than two percent; with Cathrx, Peplin, Pharmaxis and Psivida down more than one percent.

PATRYS

Patrys says it has completed preclinical safety studies for lead products PAT-LM1 and PAT-SM6 with no adverse reactions.

Patrys said PAT-SM6 had been shown to have potent anti-cancer properties in a large number of laboratory and animal studies and acted by a novel mechanism to bring about the death of cancer cells, by binding to toxic low density lipoprotein particles in the blood. Patrys said it had screened PAT-SM6 against more than 200 tumors from patients with various cancers and the product bound to more than 90 percent of the tumors.

The company said PAT-LM1 bound to a proprietary disease target expressed on the surface of cancer cells, but not on the surface of healthy tissues.

Patrys said separate trials of PAT-LM1 and PAT-SM6 conducted by Singapore's Maccine Pte Ltd began on May 18, 2009 and was completed on June 2, 2009.

The company said no adverse reactions in any of the subjects were recorded.

Patrys said the data generated provided product safety information required to gain approval for human clinical trials.

Patrys senior director of clinical operations Amos Hedt said no other natural human antibodies being developed as treatments for cancer had been tested in preclinical safety studies of this nature.

"These results positively address a previously unknown development risk," Mr Hedt said. Patrys chief executive officer Daniel Devine said PAT-LM1 and PAT-SM6 had "attributes shared by all the products in our deep pipeline, the results also have a positive impact on the value of the overall company".

The company said the evaluation of non-safety related characteristics of each product's behavior in the preclinical studies would continue through July 2009.

Patrys said that assuming no unexpected issues came from the analysis of the data, it expected to take an additional eight to 10 weeks to apply for and receive approval for human trials.

Patrys was up one cent or 11.8 percent to 9.5 cents.

FLUOROTECHNICS

Fluorotechnics says the US Patent and Trademark Office has granted a patent for "one of its most important intellectual property assets ... its unique fluorescence technology".

Fluorotechnics said it owned the intellectual property to "a new family of fluorescent molecules - the epicocconone family of fluorophores that used for detection and measurement in research, diagnostics and quality control.

The company said the granted patent described an increase in the fluorescence in a fluorescent dye which is the basis for Fluorotechnics' technology for detecting and measuring important molecules-like proteins.

Fluorotechnics chief executive officer James Walker said the granted patent was "a core patent in our intellectual property and the United States is a prime commercial target for Fluorotechnics".

"This patent strengthens the company's assets and commercial position," Mr Walker said.

The company said the method of enhancing fluorescence technology was already patented or pending by Fluorotechnics in several other jurisdictions including Europe, China and Australia. The US patent was filed on September 26, 2005.

Separately, the company announced it had relocated its Australian office and operations from Macquarie University to Unit 3, 43-51 College Street, Gladesville, New South Wales, 2111. Telephone: +61 2 9817 7400 and Fax: +61 2 9817 7433.

Fluorotechnics was untraded at 47 cents.

COMPUMEDICS

Compumedics says its newly-established Germany based sleep business has earned \$300,000 with two sleep diagnostics devices contracts.

Compumedics said Germany was the world's third largest medical device market and Europe's largest.

The company said Germany was the key driver for its growth in Europe, with more than 300 accredited sleep clinics and a market potential of about \$US36 million a year.

Compumedics said winning the contracts confirmed its "strategic advancement in developing Europe as a principal market" and the company's continued focus on key global markets.

Compumedics said the establishment of the German business followed the development of its direct-sales business in the US, responsible for about 40 percent of the annual sales of about \$40 million.

US revenues have grown from \$US1 million in 2000 to \$US13 million in 2008, a year-on-year growth of about 40 percent.

Compumedics climbed 2.5 cents or 18.5 percent to 16 cents.

ARANA

Cephalon International Holdings has extended the deadline for its Arana takeover to June 29, 2009, to pick up late acceptances.

A Cephalon spokesman told Biotech Daily that having exceeded the 90 percent level required for compulsory acquisition the extra payment of five cents a share would be made and the offer would automatically be extended to June 29, 2009.

At the close of trading last week, June 12, 2009, Cephalon held 206,163,023 Arana shares (90.41%).

Arana was up one cent or 0.72 percent to \$1.40.

SIENNA DIAGNOSTICS

Sienna has appointed Dr Ian Macreadie as chief scientific officer effective from today.

Sienna said Dr Macreadie has had "a very distinguished career in genetic research, with more than 120 publications, numerous editorial roles, more than 25 successful grants and a strong record in supporting staff and students".

The company said Dr Macreadie completed his PhD at Monash University in 1983.

His research, built on novel insights learnt in the laboratory led to his outstanding international reputation in gene expression, Sienna said.

Sienna said Dr Macreadie's background in understanding DNA, assay development and application of new technologies was "ideal" for its telomerase biosensing technology system for in vitro cancer diagnostics, through its final stages of development and adding to Sienna's existing intellectual property portfolio.

Sienna is an unlisted company, based at Melbourne's BIO-21 precinct.